Pfizer

Pfizer Inc. is a research-based biopharmaceutical company headquartered in New York. The company discovers, develops, manufactures, and commercializes medicines and vaccines for patients globally. Pfizer's marketed portfolio spans multiple therapeutic areas, and its pipeline is documented through SEC filings, FDA approval records, and clinical trial registrations. This reference page summarizes publicly verifiable positioning rather than forward-looking forecasts.

Pfizer's disclosed portfolio includes vaccines, internal medicine, oncology, inflammation and immunology, and rare disease programs. The company has expanded its oncology presence through acquisitions, including the Seagen transaction completed in 2023, which added antibody-drug conjugate and other oncology assets documented in SEC filings. Vaccines remain a core franchise, including the COVID-19 vaccine developed with BioNTech and other immunization products listed in FDA databases.

• Completed the Seagen acquisition to broaden the oncology pipeline, as disclosed in SEC merger documentation.
• Continues to emphasize business development and portfolio reshaping in investor materials filed with the SEC.
• Maintains active clinical trial registrations across oncology, vaccines, and internal medicine on ClinicalTrials.gov.
• Public filings describe ongoing cost and portfolio prioritization following the post-pandemic revenue transition.

Pfizer's pipeline and deal activity can be verified through three primary public channels: SEC periodic and current reports, FDA approval and label databases, and ClinicalTrials.gov registrations. Recent business development includes the Seagen acquisition and ongoing licensing arrangements disclosed in 8-K and 10-K filings. Readers should consult those primary sources for the latest trial status, regulatory actions, and transaction terms rather than relying on secondary summaries.